



Curriculum Vitae

Personal information **Karri Penttila**

Work experience

1. Employer: Iisalmi District Hospital
 - Start date: 101994
 - End date: 121994
 - Position: Physician in training
 - Activities:
 - Country: Finland
2. Employer: Kuopio University Hospital (KUH)
 - Start date: 011995
 - End date: 121995
 - Position: Physician in training
 - Activities: Clinical Chemistry
 - Country: Finland
3. Employer: Kuopio University, Clinical Chemistry
 - Start date: 011996
 - End date: 061996
 - Position: Researcher
 - Activities:
 - Country: Finland
4. Employer: KUH, Internal Medicine
 - Start date: 071996
 - End date: 122000
 - Position: Physician in training
 - Activities:
 - Country: Finland
5. Employer: KUH, Internal Medicine
 - Start date: 032001
 - End date: 082003
 - Position: Physician in training (Clinical Haematology)
 - Activities:
 - Country: Finland
6. Employer: Helsinki University Hospital
 - Start date: 062003
 - End date: 092003
 - Position: Clinical Haematologist (in training)
 - Activities:
 - Country: Finland
7. Employer: KUH
 - Start date: 102003
 - End date: 082010
 - Position: Clinical Haematologist /Internist
 - Activities:
 - Country: Finland
8. Employer: Finnish Medicines Agency FIMEA
 - Start date: 082010
 - End date:
 - Position: Senior Medical Officer
 - Activities:
 - Country: Finland
9. Employer: Savonlinna Central Hospital
 - Start date: 112011
 - End date:
 - Position: Clinical Haematologist, Consultant
 - Activities:
 - Country: Finland

Education and training

1. Subject: University of Kuopio
 - Start date:
 - End date:
 - Qualification: Licenciate of Medicine, 9.11.1993
 - Organisation:
 - Country: Finland
2. Subject: University of Kuopio
 - Start date:
 - End date:
 - Qualification: Specialist of Internal Medicine, 18.1. 2001
 - Organisation:
 - Country: Finland
3. Subject: University of Kuopio
 - Start date:

- End date:
 - Qualification: Clinical Haematologist, 27.10. 2003
 - Organisation:
 - Country: Finland
4. Subject: University of Kuopio
- Start date:
 - End date:
 - Qualification: Doctoral thesis, 28.11.2005
 - Organisation:
 - Country: Finland

Additional information

Publications

1: Partanen A, Turunen A, Valtola J, Pyörälä M, Vasala K, Kuittinen O, Kuitunen H, Penttilä K, Keskinen L, Kuittinen T, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study. *Transfusion*. 2020 Nov 27. doi: 10.1111/trf.16198. Epub ahead of print. PMID: 33245582.

2: Tzogani K, Penttilä K, Lähteenvuo J, Lapveteläinen T, Lopez Anglada L, Prieto C, Garcia Ochoa B, Enzmann H, Gisselbrecht C, Delgado J, Pignatti F. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma. *Oncologist*. 2020 Nov 11. doi: 10.1002/onco.13592. Epub ahead of print. PMID: 33179377.

3: Partanen A, Turunen A, Valtola J, Pyörälä M, Vasala K, Kuittinen O, Kuitunen H, Vasala K, Ågren L, Penttilä K, Keskinen L, Savolainen ER, Pyörälä M, Kuittinen T, Selander T, Mäntymaa P, Pelkonen J, Jantunen E, Varmavuo V. Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study. *Leuk Lymphoma*. 2020 Sep;61(9):2082-2092. doi: 10.1080/10428194.2020.1762879. Epub 2020 May 18. PMID: 32419549.

4: Turunen A, Partanen A, Valtola J, Ropponen A, Kuittinen O, Kuitunen H, Vasala K, Ågren L, Penttilä K, Keskinen L, Savolainen ER, Pyörälä M, Kuittinen T, Silvennoinen R, Penttilä K, Sikiö A, Vasala K, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study. *Transfusion*. 2020 Jul;60(7):1519-1528. doi: 10.1111/trf.15820. Epub 2020 Apr 24. PMID: 32333404.

5: Turunen A, Partanen A, Turunen A, Valtola J, Ropponen A, Siitonen T, Kuittinen O, Kuitunen H, Putkonen M, Sankelo M, Keskinen L, Savolainen ER, Pyörälä M, Kuittinen T, Silvennoinen R, Penttilä K, Sikiö A, Vasala K, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study. *Transfusion*. 2020 Jul;60(7):1519-1528. doi: 10.1111/trf.15820. Epub 2020 Apr 24. PMID: 32333404.

6: Partanen A, Turunen A, Valtola J, Vasala K, Ågren L, Penttilä K, Pyörälä M, Kuittinen T, Mäntymaa P, Pelkonen J, Jantunen E, Varmavuo V. A prospective comparison of pegfilgrastim and lipegfilgrastim combined with chemotherapy in the mobilization of CD34+ cells in NHL patients. *J Clin Apher*. 2020 Aug;35(4):255-263. doi: 10.1002/jca.21785. Epub 2020 Apr 20. PMID: 32282100; PMCID: 32311780.

7: Tzogani K, Penttilä K, Lapveteläinen T, Hemmings R, Koenig J, Freire J, Márcia S, Cole S, Coppola P, Flores B, Barbachano Y, Roige SD, Pignatti F. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX_351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes. *Oncologist*. 2020 Sep;25(9):e1414-e1420. doi: 10.1634/theoncologist.2019_0785. Epub 2020 Apr 13. PMID: 32282100; PMCID: 32282100.

8: Tzogani K, Florez B, Markey G, Caleno M, Olimpieri OM, Melchiorri D, Hovgaard DJ, Sarac SB, Penttilä K, Lapveteläinen T, Salmonson T, Bergh J, Gisselbrecht C, Pignatti F. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. *ESMO Open*. 2019 Sep 8;4(5):e000570. doi: 10.1136/esmoopen.2019_000570. PMID: 31555488; PMCID: PMC6735670.

9: Partanen A, Valtola J, Ropponen A, Kuitunen H, Kuittinen O, Vasala K, Ågren L, Penttilä K, Keskinen L, Nousiainen T, Selander T, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34+ cells in non-Hodgkin lymphoma patients. *Transfusion*. 2019 Jan;59(1):325-334. doi: 10.1111/trf.14993. Epub 2018 Nov 19. PMID: 30450652.

10: Partanen A, Valtola J, Ropponen A, Vasala K, Penttilä K, Ågren L, Pyörälä M, Nousiainen T, Selander T, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly. *Ann Hematol*. 2017 Nov;96(11):1897-1906. doi: 10.1007/s00277-017-3123-6. Epub 2017 Sep 7. PMID: 28879595.

11: Pauwels K, Huys I, Casteels M, Larsson K, Voltz C, Penttilä K, Morel T, Simoens S. Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012. *Orphanet J Rare Dis*. 2017 Feb 16;12(1):36. doi: 10.1186/s13023-017-0578-4. PMID: 28209180; PMCID: PMC5314481.

12: Penttilä I, Penttilä K, Holm P, Laitinen H, Ranta P, Törrönen J, Rauramaa R. Methods, units and quality requirements for the analysis of haemoglobin A1c in diabetes mellitus. *World J Methodol*. 2016 Jun 26;6(2):133-42. doi: 10.5662/wjm.v6.i2.133. PMID: 27376018; PMCID: PMC4921944.

13: Penttilä I, Penttilä K, Holm P, Laitinen H, Rauramaa R. Hemoglobin A1c reported in units and diagnostic cut-offs in relation to the international recommendations. *Clin Chem Lab Med*. 2015 Aug;53(9):e215-7. doi: 10.1515/cclm.2015.0247. PMID: 26136301.

14: Valtola J, Varmavuo V, Ropponen A, Nihtinen A, Partanen A, Vasala K, Lehtonen P, Penttilä K, Pyörälä M, Kuittinen T, Silvennoinen R, Nousiainen T, Pelkonen J, Mäntymaa P, Jantunen E. Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison. *Transfusion*. 2015 Oct;55(10):2358-68. doi: 10.1111/trf.13170. Epub 2015 May 28. PMID: 26018461.

15: Silvennoinen R, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Säily M, Sikiö A, Opas J, Penttilä K, Kuittinen T, Honkanen T, Lundán T, Juvonen V, Luukkaala T, Remes K. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients. *Br J Haematol*. 2013 Feb;160(4):561-4. doi: 10.1111/bjh.12139. Epub 2012 Dec 4. PMID: 23206270.

16: Penttilä I, Penttilä K, Halonen T, Pulkki K, Törrönen J, Rauramaa R. Adaptation of the Diazyme Direct Enzymatic HbA1c Assay for a microplate reader at room temperature. *Clin Chem Lab Med*. 2011 Jul;49(7):1221-3. doi: 10.1515/CCLM.2011.186. Epub 2011 May 17. PMID: 21574882.

17: Jantunen E, Penttilä K, Pyörälä M, Mahlamäki E, Kuittinen T, Nousiainen T. Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients. *Bone Marrow Transplant*. 2011 Feb;46(2):308-9. doi: 10.1038/bmt.2010.93. Epub 2010 Apr 19. PMID: 20400986.

18: Penttilä I, Penttilä K, Halonen T, Pulkki K, Törrönen J, Rauramaa R. Adaptation of the Diazyme Direct Enzymatic HbA1c Assay for a microplate reader at room temperature. *Clin Chem Lab Med*. 2011 Jul;49(7):1221-3. Epub 2011 May 17. PMID: 21574882.

19: Jantunen E, Penttilä K, Pyörälä M, Mahlamäki E, Kuittinen T, Nousiainen T. Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients. *Bone Marrow Transplant*. 2010 Apr 19. [Epub ahead of print] PubMed PMID: 20400986.

20: Ervasti M, Penttilä K, Siltari S, Delezuch W, Punnonen K. Diagnostic, clinical and laboratory turnaround times in troponin T testing. *Clin Chem Lab Med*. 2008;46(7):1030-2. PubMed PMID: 18605943.

21: Penttilä IM, Laatikainen A, Penttilä K, Punnonen K, Rantanen T, Savolainen K, Tiikkainen U. Imprecision of cardiac marker analyses among laboratories on the basis of external quality assurance results: Finnish experience. *Scand J Clin Lab Invest*. 2007;67(5):507-18. PubMed PMID: 17763187.

22: Jantunen E, Heinonen K, Mahlamäki E, Penttilä K, Kuittinen T, Lehtonen P, Pyörälä M, Hänninen A, Nousiainen T. Secondary acute promyelocytic leukemia: an increasingly common entity. *Leuk Lymphoma*. 2007 Jan;48(1):190-1. PubMed PMID: 17325866.

23: Jantunen E, Kuittinen T, Penttilä K, Lehtonen P, Mahlamäki E, Nousiainen T. High-dose melphalan (200 mg/m²) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol. *Bone Marrow Transplant*. 2006 May;37(10):917-22. PubMed PMID: 16670701.

24: Jantunen E, Penttilä K, Kuittinen T, Nousiainen T. [The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease]. *Duodecim*. 2006;122(4):453-7. Finnish. PubMed PMID: 16623100.

25: Penttilä K, Koukkunen H, Halinen M, Punnonen K, Pyörälä K, Rantanen T, Penttilä I. Serum and plasma as alternative sample types in analysis of cardiac markers in the clinical routine. *Scand J Clin Lab Invest*. 2002;62(7):553-60. PubMed PMID: 12512746.

26: Penttilä K, Koukkunen H, Halinen M, Rantanen T, Pyörälä K, Punnonen K, Penttilä I. Myoglobin, creatine kinase MB isoforms and creatine kinase MB mass in early diagnosis of myocardial infarction in patients with acute chest pain. *Clin Biochem*. 2002 Nov;35(8):647-53. PubMed PMID: 12499000.

27: Koukkunen H, Penttilä K, Kempainen A, Penttilä I, Halinen M, Rantanen T, Pyörälä K. Ruling out myocardial infarction with

troponin T and creatine kinase MB mass: diagnostic and prognostic aspects. Scand Cardiovasc J. 2001 Oct;35(5):302_6. PubMed PMID: 11771820. 28: Koukkunen H, Penttilä K, Kemppainen A, Penttilä I, Halinen MO, Rantanen T, Pyörälä K. Differences in the diagnosis of myocardial infarction by troponin T compared with clinical and epidemiologic criteria. Am J Cardiol. 2001 Oct 1;88(7):727_31. PubMed PMID: 11589837. 29: Koukkunen H, Penttilä K, Kemppainen A, Halinen M, Penttilä I, Rantanen T, Pyörälä K. C-reactive protein, fibrinogen, interleukin_6 and tumour necrosis factor_alpha in the prognostic classification of unstable angina pectoris. Ann Med. 2001 Feb;33(1):37_47. PubMed PMID: 11310937. 30: Penttilä I, Penttilä K, Rantanen T. Laboratory diagnosis of patients with acute chest pain. Clin Chem Lab Med. 2000 Mar;38(3):187_97. Review. PubMed PMID: 10905753. 31: Penttilä K, Koukkunen H, Kemppainen A, Halinen M, Rantanen T, Pyörälä K, Penttilä I. Myoglobin, creatine kinase MB, troponin T, and troponin I _ rapid bedside assays in patients with acute chest pain. Int J Clin Lab Res. 1999;29(2):93_101. PubMed PMID: 10436269. 32: Koukkunen H, Penttilä K, Kemppainen A, Halinen M, Penttilä I, Rantanen T, Pyörälä K. Troponin T and creatinine kinase isoenzyme MB mass in the diagnosis of myocardial infarction. Ann Med. 1998 Oct;30(5):488_96. PubMed PMID: 9814836. 33: Penttilä K, Penttilä I, Bonnell R, Kerth P, Koukkunen H, Rantanen T, Svanas G. Comparison of the troponin T and troponin I ELISA tests, as measured by microplate immunoassay techniques, in diagnosing acute myocardial infarction. Eur J Clin Chem Clin Biochem. 1997 Oct;35(10):767_74. PubMed PMID: 9368795. 34: Kröger H, Jurvelin J, Arnala I, Penttilä K, Rask A, Vainio P, Alhava E. Ultrasound attenuation of the calcaneus in normal subjects and in patients with wrist fracture. Acta Orthop Scand. 1995 Feb;66(1):47_52. PubMed PMID: 7863768. 35: Penttilä I, Hirvonen K, Julkunen A, Penttilä K, Rantanen T. Adaptation of the troponin T ELISA test to a microplate immunoassay reader. Eur J Clin Chem Clin Biochem. 1995 Jan;33(1):59_63. PubMed PMID: 7756442.

Projects

Memberships

Finnish Medical Association, Finnish Medical Society Duodecim, Finnish Society of Haematology

Other Relevant Information